Enanta Pharmaceuticals Executive Compensation (FY25)
ENTA · Executive and director compensation, fiscal 2025 only
The Enanta Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): March 12, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
108 figures on this page: 106 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
Frequently asked questions
Answers drawn from the data on this page.
Who is Enanta Pharmaceuticals' chief executive and what were they paid?
Jay Luly, President and Chief Executive Officer, received $2,769,548 in total compensation for fiscal 2025.
What was Enanta Pharmaceuticals' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 97.2% support at the meeting held March 11, 2026.
Which companies are in Enanta Pharmaceuticals' peer group?
The disclosed peer group names Allogene Therapeutics, Altimmune, Arcturus Therapeutics, Heron Therapeutics and Inovio Pharmaceuticals, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jay Luly President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Scott Rottinghaus Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Yat Sun Or Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Jay Luly | PSU | — | — | — | — | — | — | ◇ |
| Jay Luly | OPTION | — | — | — | — | — | — | ◇ |
| Scott Rottinghaus | PSU | — | — | — | — | — | — | ◇ |
| Scott Rottinghaus | OPTION | — | — | — | — | — | — | ◇ |
| Yat Sun Or | PSU | — | — | — | — | — | — | ◇ |
| Yat Sun Or | OPTION | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Scott Rottinghaus | Option | ◇ | — | ◇ | 8/8/2032 |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/22/2033 | |
| Option | ◇ | — | ◇ | 11/27/2034 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/23/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Jay Luly | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/23/2032 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/22/2033 | |
| Option | ◇ | — | ◇ | 11/27/2034 | |
| Option | ◇ | — | ◇ | 11/19/2031 | |
| Yat Or | Option | ◇ | — | ◇ | 11/23/2032 |
| Option | ◇ | — | ◇ | 11/27/2034 | |
| Option | ◇ | — | ◇ | 11/22/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/19/2031 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Bruce L.A. Carter, Ph.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Terry C. Vance | ◇ | — | ◇ | — | — | — | ◇ |
Mark G. Foletta | ◇ | — | ◇ | — | — | — | ◇ |
Kristine Peterson | ◇ | — | ◇ | — | — | — | ◇ |
Lesley Russell, MBChB, MRCP | ◇ | — | ◇ | — | — | — | ◇ |
Yujiro Hata | ◇ | — | ◇ | — | — | — | ◇ |
Jay R. Luly, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Stock Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Allogene Therapeutics ALLO
- Altimmune ALT
- Arcturus Therapeutics ARCT
- Heron Therapeutics HRTX
- Inovio Pharmaceuticals INO
- Karyopharm Therapeutics KPTI
- Lexicon Pharmaceuticals LXRX
- Nektar Therapeutics NKTR
- Rigel Pharmaceuticals RIGL
- Sage Therapeutics SAGE
- Travere Therapeutics TVTX
- Vanda Pharmaceuticals VNDA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | March 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | March 13, 2025 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Enanta Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Enanta Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
108 figures on this page: 106 cited to the filing that reported them, 2 calculated from figures it prints.
106 cited to the filing
2 calculated from the filing
Documents cited
- 0001193125-26-104109Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-022558DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal 2025 Year-End · Summary Compensation Table
- 0000950170-25-040230Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Enanta Pharmaceuticals executive compensation, FY2025.” https://intel.velarion.ai/comp/ENTA (accessed 2026).
Short form: data: Velarion
The Enanta Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Enanta Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Enanta Pharmaceuticals discloses
The companies named in ENTA's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}